journal article·2024-09Open access

Autophagy Deficiency Induced by SAT1 Potentiates Tumor Progression in Triple‐Negative Breast Cancer

Wenwen Tian, Lewei Zhu, Yongzhou Luo, Yuhui Tang, Qingjian Tan, Yutian Zou, Kun Chen, Xinpei Deng, Hailin Tang, Hongsheng Li, Manbo Cai, Xiaoming Xie, Feng Ye

Advanced Science· Volume 11· Issue 36

Abstract

Abstract Aggressive triple‐negative breast cancer (TNBC) still lacks approved targeted therapies, requiring more exploration of its underlying mechanisms. Previous studies have suggested a potential role of SAT1 (Spermidine/Spermine N1‐acetyltransferase 1) in cancer, which needs to be further elucidated in breast cancer. In this study, highly expressed SAT1 in TNBC signified worse patient prognoses. And SAT1 knockdown effectively inhibited the proliferation and migration abilities of TNBC cells in vitro and in vivo. In terms of mechanism, the transcription factor JUN enhanced SAT1 transcriptional activity by binding to its promoter region. Then, SAT1 protein in the cytoplasm engaged in directly binding with YBX1 for sustaining YBX1 protein stability via deubiquitylation mediated by the E3 ligase HERC5. Further, SAT1 was found to suppress autophagy remarkably via stabilization of mTOR mRNA with the accumulation of YBX1‐mediated methyl‐5‐cytosine (m5C) modification. These findings proved that SAT1 drives TNBC progression through the SAT1/YBX1/mTOR axis, which may provide a potential candidate for targeted therapy in advanced TNBC.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Autophagy in Disease and Therapy · Cancer-related gene regulation · Epigenetics and DNA Methylation

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

State Key Laboratory of Oncology in South China Guangdong Provincial Clinical Research Center for Cancer Sun Yat‐sen University Cancer Center Guangzhou 510060 P. R. China

Guangzhou Institute of Cancer Research, the Affiliated Cancer Hospital, Guangzhou Medical University Guangzhou 510095 P. R. China

The First People's Hospital of Foshan Foshan 528000 P. R. China

The First Affiliated Hospital Hengyang Medical School University of South China Hengyang Hunan 421001 P. R. China

Funding

Basic and Applied Basic Research Foundation of Guangdong Province · National Natural Science Foundation of China

References (60)

Show source-provided references
1. 10.1038/nrendo.2010.9210.1038/nrendo.2010.92 ↗
2. 10.3322/caac.2176310.3322/caac.21763 ↗
3. 10.1158/2159-8290.CD-18-117710.1158/2159-8290.CD-18-1177 ↗
4. 10.1093/annonc/mds18810.1093/annonc/mds188 ↗
5. 10.1016/j.gene.2019.14401010.1016/j.gene.2019.144010 ↗
6. 10.1042/BJ2009059810.1042/BJ20090598 ↗
7. 10.1038/s41388-019-0917-010.1038/s41388-019-0917-0 ↗
8. 10.1158/0008-5472.CAN-14-124910.1158/0008-5472.CAN-14-1249 ↗
9. 10.1073/pnas.160715211310.1073/pnas.1607152113 ↗
10. 10.1002/advs.20220369910.1002/advs.202203699 ↗
11. 10.1016/j.gendis.2015.05.00110.1016/j.gendis.2015.05.001 ↗
12. 10.1186/bcr176710.1186/bcr1767 ↗
13. 10.1158/0008-5472.CAN-13-246610.1158/0008-5472.CAN-13-2466 ↗
14. 10.1186/s12885-017-3187-710.1186/s12885-017-3187-7 ↗
15. 10.1038/s41556-019-0361-y10.1038/s41556-019-0361-y ↗
16. 10.1002/wrna.163910.1002/wrna.1639 ↗
17. 10.1038/s41388-021-01978-010.1038/s41388-021-01978-0 ↗
18. 10.1038/s41419-021-04127-310.1038/s41419-021-04127-3 ↗
19. 10.1016/j.semcancer.2019.11.00810.1016/j.semcancer.2019.11.008 ↗
20. 10.1158/0008-5472.CAN-13-296610.1158/0008-5472.CAN-13-2966 ↗
21. 10.4161/auto.3439810.4161/auto.34398 ↗
22. 10.1038/s41374-019-0249-210.1038/s41374-019-0249-2 ↗
23. 10.1126/scitranslmed.abn757110.1126/scitranslmed.abn7571 ↗
24. 10.1016/j.semcancer.2019.08.00310.1016/j.semcancer.2019.08.003 ↗
25. 10.1093/nar/gkab111310.1093/nar/gkab1113 ↗
26. 10.1158/1078-0432.CCR-13-206010.1158/1078-0432.CCR-13-2060 ↗
27. 10.1016/j.apsb.2022.05.00910.1016/j.apsb.2022.05.009 ↗
28. 10.1038/s41419-020-2555-410.1038/s41419-020-2555-4 ↗
29. 10.1016/j.omtn.2020.10.02510.1016/j.omtn.2020.10.025 ↗
30. 10.1038/s41467-020-17395-y10.1038/s41467-020-17395-y ↗
31. 10.1038/cdd.2010.11510.1038/cdd.2010.115 ↗
32. 10.3389/fimmu.2023.120737110.3389/fimmu.2023.1207371 ↗
33. 10.1186/s12967-022-03427-210.1186/s12967-022-03427-2 ↗
34. 10.1016/j.canlet.2023.21612410.1016/j.canlet.2023.216124 ↗
35. 10.1186/s12885-022-09313-w10.1186/s12885-022-09313-w ↗
36. 10.7150/thno.2513010.7150/thno.25130 ↗
37. 10.1038/s41556-018-0042-210.1038/s41556-018-0042-2 ↗
38. 10.1158/2159-8290.CD-19-029210.1158/2159-8290.CD-19-0292 ↗
39. 10.1016/j.molcel.2022.03.02310.1016/j.molcel.2022.03.023 ↗
40. 10.1016/j.semcancer.2020.03.01010.1016/j.semcancer.2020.03.010 ↗
41. 10.1038/4525710.1038/45257 ↗
42. 10.1016/j.ebiom.2015.01.00810.1016/j.ebiom.2015.01.008 ↗
43. 10.1007/s10549-012-2080-y10.1007/s10549-012-2080-y ↗
44. 10.1038/s41467-023-37161-010.1038/s41467-023-37161-0 ↗
45. 10.1016/j.jhep.2021.08.02710.1016/j.jhep.2021.08.027 ↗
46. 10.1182/blood.202000967610.1182/blood.2020009676 ↗
47. 10.1016/j.canlet.2021.04.02510.1016/j.canlet.2021.04.025 ↗
48. 10.1158/0008-5472.CAN-17-115310.1158/0008-5472.CAN-17-1153 ↗
49. 10.1038/s41419-023-05564-y10.1038/s41419-023-05564-y ↗
50. 10.1016/j.canlet.2024.21685610.1016/j.canlet.2024.216856 ↗
51. Bezu L. · Front. Immunol. · 2015 · 6 · 187
52. 10.7150/ijbs.8193910.7150/ijbs.81939 ↗
53. 10.3389/fimmu.2022.105668010.3389/fimmu.2022.1056680 ↗
54. 10.3389/fimmu.2022.84351510.3389/fimmu.2022.843515 ↗
55. 10.1038/s41420-023-01771-w10.1038/s41420-023-01771-w ↗
56. 10.1186/s13045-020-00852-y10.1186/s13045-020-00852-y ↗
57. 10.1016/j.drup.2024.10106310.1016/j.drup.2024.101063 ↗
58. 10.1016/j.canlet.2023.21650810.1016/j.canlet.2023.216508 ↗
59. 10.1038/s41419-023-06115-110.1038/s41419-023-06115-1 ↗
60. 10.1038/s41418-020-00627-510.1038/s41418-020-00627-5 ↗